How to Buy Niagen Bioscience Stock
Niagen Bioscience Inc
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
Niagen Bioscience stock last closed at $2.68, down 8.22% from the previous day, and has decreased 66.03% in one year. It has overperformed other stocks in the Biotechnology industry by 0.08 percentage points. Niagen Bioscience stock is currently +0.37% from its 52-week low of $2.67, and -66.29% from its 52-week high of $7.95.
There are currently 79.13M shares of NAGE outstanding. The market value of NAGE is $212.06M. In the past 24 hours, 1.39M NAGE shares were traded.
How to Buy Niagen Bioscience Stock
Wondering how to invest in Niagen Bioscience stock? Here's how.
- Choose where to buy Niagen Bioscience stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Niagen Bioscience stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Choose your method of payment and add your information.
- Analyze Niagen Bioscience stock: The Niagen Bioscience ticker symbol is NAGE. Is Niagen Bioscience stock a good investment? Should you buy shares of NAGE? How do NAGE's underlying business fundamentals look? Do top analysts think Niagen Bioscience is a good buy? Why has NAGE's stock price moved recently? (Hint: Our stock market research tools can help you evaluate if NAGE is a good stock to buy).
- Execute your NAGE purchase: Decide if you will purchase NAGE shares at the current market price or use a limit order to buy NAGE shares at a particular price.
- Get the latest news on your NAGE position: Create a watchlist to watch your investment in Niagen Bioscience stock.
Step 1: Choose where to buy Niagen Bioscience stock
You need a brokerage account to access the NASDAQ market and buy NAGE stock.
Our recommended brokerage: eToro
Based on our research, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal details so you are able to invest in NAGE stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have finished signing up on the best stock broker app, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing funds into your investment account.
Step 4: Analyze Niagen Bioscience stock
Once you have chosen the best place to buy Niagen Bioscience stock, it's absolutely critical to research their stock prior to buying, so you truly wrap your head around the risk and upside.
Niagen Bioscience stock quick numbers
Niagen Bioscience Overview
WallStreetZen was built to help part-time investors do more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on NAGE's stock page.
Is NAGE stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge NAGE's true value.
Using relative valuations ratios:
- NAGE may be overvalued based on its P/E ratio of 13.4x, relative to Biotechnology industry P/E ratio of 8.71x
- NAGE could be undervalued based on its P/B ratio of 2.57x, relative to Biotechnology industry P/B ratio of 5.13x
You can access additional valuation analysis on NAGE's stock here.
NAGE Financials at a glance
Positive Financial Indicators:
- NAGE's operating cash flow of $5.95M allows it to safely service it's debt of $2.33M.
- There are more short-term assets than long-term liabilities on the NAGE balance sheet.
- NAGE earnings of $17.03M is not enough to cover its interest payments.
- NAGE has a low debt to equity ratio of 0.29.
- There are more short-term assets than short-term liabilities on the NAGE balance sheet.
- Total NAGE debt is lower than 5 years ago, relative to shareholder equity.
Negative Financial Indicators:
- NAGE profit margin has gone down from 15.2% to 12.4% in the past year.
Is it a good time to buy NAGE stock, according to analysts?
Out of 2 sell side analysts who track NAGE, the consensus analyst rating on NAGE is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are forecasting on the Niagen Bioscience stock forecast page.
NAGE Technical Indicators
NAGE Performance Metrics
Last year, NAGE earnings were $15.99M. During the past 1 years, NAGE's earnings have increased by -13.04% per year. This was slower than the Biotechnology industry average of 9.56%.
Last year, NAGE revenue was $129.08M. Over the last five year, NAGE's revenue has increased by 15.79% per year. This was slower than the Biotechnology industry average of 32.38%.
Find out more about NAGE's earnings and revenue performance here.
Latest Insiders Trades at NAGE
Over the last year, executives and large shareholders at NAGE have bought more shares than they have sold.
Robert N. Fried, Chief Executive Officer of NAGE, was the latest NAGE insider to buy. They bought $2,997.26 worth of NAGE shares on Jun 30, 2026.
Learn more about who owns NAGE stock here.
Can I get consistent income from NAGE stock?
No, Niagen Bioscience doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your NAGE purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given price, use a limit order.
Click the Open button and your broker will place the order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Get the latest news on your NAGE position
Now that you own some NAGE stock, you'll want to stay up-to-date on your investment.
Put NAGE on a watchlist to get the latest updates about your NAGE stock.
NAGE Feed
How to Buy Stock in Niagen Bioscience
To reiterate, here are the 6 steps to buy stock in Niagen Bioscience:
- Choose where to buy Niagen Bioscience stock
- Open a brokerage account
- Deposit money your investment account
- Analyze Niagen Bioscience stock
- Execute your NAGE purchase
- Get the latest news on your NAGE position
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your investment in Niagen Bioscience, create a watchlist on WallStreetZen today.
Other Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.